Seeking Alzheimer’s clues from few who escape genetic fateAP News - March 16, 2023
Lifetime Achievement AwardClinical Trials on Alzheimer's Disease (CTAD) - March14, 2023
Focused ultrasound technique leads to release of neurodegenerative disorders biomarkersThe Source, Washington University in St. Louis - Feb 3, 2023
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for...
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASEEisai Co., Ltd. - Jan 06 2023
Update on the DIAN-TU-002 Primary Prevention Trial
20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...
WashU, Eisai form drug discovery collaborationThe Source, Washington University in St. Louis - Dec 14, 2022
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s diseaseRoche - Nov 14, 2022
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...